Clinical Commander

Back to dossier
cardio.cardiogenic-shock.takotsubo.v1PRODUCTION
cardio.cardiogenic-shock.takotsubo.v1

Cardiogenic shock — Takotsubo (stress) cardiomyopathy

cardiologyacuteadult
Hard-required inputs
0 / 12
Care setting:

Encounter flow

11/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

Confirm Takotsubo with cardiogenic shock per InterTAK criteria (Ghadri 2018) — apical (or atypical) ballooning + ABSENCE of obstructive CAD on cath + recent stressor + postmenopausal predominance; CS variant means SCAI Stage C+ overlay

Inputs
2
Actions
0
Advance rule
Set
Advance when

Takotsubo confirmed + CS overlay documented

Patient inputs (13)

Mandatory rule-out of obstructive CAD per Ghadri 2018 InterTAK criteria; LV gram confirms apical ballooning pattern

Postmenopausal female (~90%) predominant; estrogen deficiency hypothesis; informs gender-specific catecholamine sensitivity

InterTAK registry — ~90% female, ~80% age >50; major epidemiologic anchor (Templin NEJM 2015 PMID 26332547)

Tachycardia worsens LVOT obstruction subtype — gates β-blocker (esmolol) decision in that variant

End-organ damage marker; eGFR for dosing of supportive agents

Identifying trigger (emotional vs physical) drives prognosis — physical-stressor Takotsubo has higher mortality than emotional per InterTAK PMID 26332547

Modest rise typical (much lower than expected for degree of LV dysfunction); discordance is a Takotsubo clue per Ghadri 2018 InterTAK criteria

BNP/NT-proBNP often markedly elevated (disproportionate to troponin) — Takotsubo discordance pattern

Apical ballooning + RWMA crossing single coronary territory; LVOT gradient measurement (15–25% subset); pericardial effusion screen

Diffuse T-wave inversion + QT prolongation typical; rule out STEMI; ST elevation possible (mimics LAD STEMI); marked QT prolongation (>500 ms) carries torsades risk

SCAI 2022 staging baseline + LVOT-obstruction subtype gating (low SBP + dynamic gradient = LVOT-obstruction Takotsubo)

SCAI 2022 staging + response to therapy; Takotsubo CS often has rapid lactate resolution with supportive care + recovery

Confirms regional wall motion + edema (T2) + ABSENT LGE (vs ischemic CMP); helpful when cath ambiguous or for atypical patterns

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (5)

5 need judgement
  • informationallife_threateningmcs_escalation_needed_for_takotsubo_cs
    Refractory Takotsubo CS despite cautious NE — escalate to MCS (IABP / Impella / VA-ECMO) for bridge to recovery rather than escalating pressors / inotropes (which worsen catecholamine excess)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningqt_prolongation_with_torsades_risk
    QT prolongation >500 ms in Takotsubo + electrolyte derangement (K <4 OR Mg <2) — torsades risk; aggressive electrolyte replacement + telemetry; MgSO4 + temporary pacing if torsades develops
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseverelvot_obstruction_discovered_in_takotsubo_cs
    Significant dynamic LVOT gradient (≥30 mmHg at rest or ≥50 mmHg with provocation) in Takotsubo CS — requires opposite physiology pathway: β-blocker (esmolol) + IV fluids + phenylephrine; AVOID inotropes / diuretics
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalsevererecurrent_takotsubo_episode
    Recurrent Takotsubo episode (~5–10% lifetime rate per InterTAK PMID 26332547) — re-evaluate trigger management, stressor mitigation, consider long-term β-blocker / ARNI debate
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseveremural_thrombus_from_apical_akinesia
    LV apical thrombus on echo OR severe apical akinesia + EF <35 in Takotsubo — initiate AC × 3 mo (warfarin INR 2–3 or apixaban 5 mg BID); risk peaks while LV remains dysfunctional
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

Run this disease's risk and dosing calculators inline.

RED_FLAGSrequiredDrives risk stratification
Loading…

Recommended regimen

Takotsubo CS — subtype-aware support; AVOID inotropes / β-blocker (non-LVOT subtype); LVOT subtype requires β-blocker + fluids + phenylephrine; MCS for bridge to recovery
axis: takotsubo_cs_phenotype
Selected axis "Takotsubo CS — subtype-aware support; AVOID inotropes / β-blocker (non-LVOT subtype); LVOT subtype requires β-blocker + fluids + phenylephrine; MCS for bridge to recovery" by default fallback (first axis)
  • norepinephrine
    first line
    vasopressor_alpha
    0.03–0.2 µg/kg/min CAUTIOUS titration (lower than standard CS to avoid catecholamine excess) • IV • continuous; titrate to MAP ≥65
    triggers: takotsubo_cs_non_lvot_subtype, sbp_lt_90
    SOAP-II PMID 20200382 — NE first-line in CS; in Takotsubo use lowest effective dose to avoid worsening catecholamine excess; preferred over inotropes
    rxcui 7512
  • phenylephrine
    first line
    vasopressor_pure_alpha
    40–360 µg/min IV • IV • continuous
    triggers: takotsubo_cs_lvot_obstruction_subtype, need_pure_alpha_pressor_to_avoid_inotropy
    Pure α-agonist; preferred in LVOT-obstruction subtype because it raises afterload without inotropy (which worsens dynamic obstruction); ESC HFA 2016 Lyon position
    rxcui 8163
  • esmolol
    first line
    short_acting_beta_blocker
    500 µg/kg bolus then 50–200 µg/kg/min • IV • continuous, titrate
    triggers: takotsubo_cs_lvot_obstruction_subtype, dynamic_lvot_gradient_significant
    LVOT-obstruction Takotsubo subset (15–25%) — β-blocker reduces dynamic gradient and improves forward flow; esmolol short-acting allows rapid titration; AVOID in non-LVOT subtype
    rxcui 49737
  • isotonic crystalloid (LR or NS)
    first line
    isotonic_crystalloid
    250–500 mL bolus • IV • reassess after each bolus
    triggers: takotsubo_cs_lvot_obstruction_subtype, preload_dependent_physiology
    In LVOT-obstruction subtype, IV fluids increase LV cavity size and reduce dynamic gradient; AVOID in non-LVOT subtype with pulmonary edema
    rxcui 4337
  • warfarin
    comorbidity specific
    vitamin_k_antagonist
    5 mg daily; INR target 2–3 • PO • daily × 3 mo
    triggers: takotsubo_with_severe_apical_akinesia, ef_lt_35_with_apical_ballooning_persistent, lv_thrombus_on_echo
    AHA 2022 Class IIa for LV thrombus (extrapolated); apical-ballooning Takotsubo carries mural-thrombus risk while LV remains dysfunctional; 3-mo course typically sufficient given recovery timeline
    rxcui 11289
  • apixaban
    comorbidity specific
    doac_factor_xa_direct
    5 mg BID (or 2.5 mg BID per dose-reduction criteria) • PO • BID × 3 mo for mural thrombus prophylaxis
    triggers: takotsubo_with_apical_akinesia_warfarin_intolerant, patient_compliance_concern_with_inr_monitoring
    Off-label-but-rational DOAC alternative for LV thrombus prophylaxis; small RCTs support non-inferiority to warfarin in LV thrombus
    rxcui 1364430
  • sacubitril-valsartan
    add on
    arni
    24/26 BID (consider after recovery; debated indication) • PO • BID
    triggers: persistent_lv_dysfunction_beyond_8_weeks, documented_chronic_HFrEF_after_recovery_attempt
    No RCT-grade evidence in Takotsubo recovery; case-by-case consideration if persistent HFrEF beyond expected recovery window per Lyon 2016 ESC HFA position
    rxcui 1656328

outpatient playbook — drug actions (2)

  1. 1. discontinue warfarin / apixaban at 3 mo if EF recovered + apical akinesia resolved
    taper / stop per AHA 2022 LV thrombus consensus • PO • n/a
    trigger: Normalized echo at 3 mo
    Mural thrombus risk resolves with LV recovery; 3-mo course typically sufficient
  2. 2. continue or up-titrate ACEi / BB if persistent LV dysfunction
    lisinopril 10–40 + carvedilol 3.125 → 25 BID • PO • daily/BID
    trigger: Persistent EF<50 beyond 8 wks (rare)
    Lyon 2016 ESC HFA position — case-by-case for the rare persistent-dysfunction subset

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: Bedside echo: apical ballooning (or midventricular / basal / focal pattern) + LV dysfunction + shock physiology — Takotsubo cardiomyopathy with CS; Recent severe emotional (death of loved one, divorce) or physical (surgery, sepsis, severe illness) stressor in postmenopausal female (~90% predominance) presenting with shock; Cath: no obstructive CAD + LV gram showing apical ballooning + RWMA crossing single coronary territory — InterTAK criteria (Ghadri 2018).

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**Cardiogenic shock — Takotsubo (stress) cardiomyopathy** (cardio.cardiogenic-shock.takotsubo.v1).
Scope: Confirm Takotsubo with cardiogenic shock per InterTAK criteria (Ghadri 2018) — apical (or atypical) ballooning + ABSENCE of obstructive CAD on cath + recent stressor + postmenopausal predominance; CS variant means SCAI Stage C+ overlay

No severity triggers fired against current inputs.

Plan

Regimen axis: **Takotsubo CS — subtype-aware support; AVOID inotropes / β-blocker (non-LVOT subtype); LVOT subtype requires β-blocker + fluids + phenylephrine; MCS for bridge to recovery**.
1. norepinephrine 0.03–0.2 µg/kg/min CAUTIOUS titration (lower than standard CS to avoid catecholamine excess) IV continuous; titrate to MAP ≥65 (vasopressor_alpha, first line) — SOAP-II PMID 20200382 — NE first-line in CS; in Takotsubo use lowest effective dose to avoid worsening catecholamine excess; preferred over inotropes
2. phenylephrine 40–360 µg/min IV IV continuous (vasopressor_pure_alpha, first line) — Pure α-agonist; preferred in LVOT-obstruction subtype because it raises afterload without inotropy (which worsens dynamic obstruction); ESC HFA 2016 Lyon position
3. esmolol 500 µg/kg bolus then 50–200 µg/kg/min IV continuous, titrate (short_acting_beta_blocker, first line) — LVOT-obstruction Takotsubo subset (15–25%) — β-blocker reduces dynamic gradient and improves forward flow; esmolol short-acting allows rapid titration; AVOID in non-LVOT subtype
4. isotonic crystalloid (LR or NS) 250–500 mL bolus IV reassess after each bolus (isotonic_crystalloid, first line) — In LVOT-obstruction subtype, IV fluids increase LV cavity size and reduce dynamic gradient; AVOID in non-LVOT subtype with pulmonary edema
5. warfarin 5 mg daily; INR target 2–3 PO daily × 3 mo (vitamin_k_antagonist, comorbidity specific) — AHA 2022 Class IIa for LV thrombus (extrapolated); apical-ballooning Takotsubo carries mural-thrombus risk while LV remains dysfunctional; 3-mo course typically sufficient given recovery timeline
6. apixaban 5 mg BID (or 2.5 mg BID per dose-reduction criteria) PO BID × 3 mo for mural thrombus prophylaxis (doac_factor_xa_direct, comorbidity specific) — Off-label-but-rational DOAC alternative for LV thrombus prophylaxis; small RCTs support non-inferiority to warfarin in LV thrombus
7. sacubitril-valsartan 24/26 BID (consider after recovery; debated indication) PO BID (arni, add on) — No RCT-grade evidence in Takotsubo recovery; case-by-case consideration if persistent HFrEF beyond expected recovery window per Lyon 2016 ESC HFA position

Setting playbook (outpatient) — 4–8 week recovery echo — confirm complete LV recovery (typical); discontinue mural-thrombus AC at 3 mo if EF normalized + apical akinesia resolved; long-term ARNI / BB debated case-by-case if residual dysfunction; psych follow-up + recurrence education
8. discontinue warfarin / apixaban at 3 mo if EF recovered + apical akinesia resolved taper / stop per AHA 2022 LV thrombus consensus PO n/a — Normalized echo at 3 mo (Mural thrombus risk resolves with LV recovery; 3-mo course typically sufficient)
9. continue or up-titrate ACEi / BB if persistent LV dysfunction lisinopril 10–40 + carvedilol 3.125 → 25 BID PO daily/BID — Persistent EF<50 beyond 8 wks (rare) (Lyon 2016 ESC HFA position — case-by-case for the rare persistent-dysfunction subset)

Non-pharmacologic actions:
- Recurrence education — ~5–10% over follow-up per InterTAK PMID 26332547
- Stressor mitigation counseling (psych referral if not already engaged)
- Cardiac rehab if persistent LV dysfunction

AVOID / contraindication checks:
- Beta_blocker_AVOID_in_non_lvot_takotsubo (paradoxical worsening; catecholamine sensitization; ESC HFA 2016 Lyon position)
- Inotropes_AVOID_in_takotsubo_cs (worsen catecholamine excess; epinephrine + dobutamine + milrinone all relatively contraindicated; SOAP II + ESC HFA 2016)
- Diuretics_AVOID_in_lvot_obstruction_subtype (preload dependent physiology; reduces LV cavity size and worsens gradient)
- Nitrates_AVOID_in_lvot_obstruction_subtype (preload reduction worsens dynamic gradient)
- Lv_only_impella_consider_carefully_in_takotsubo (apical positioning may be limited by apical akinesia / mural thrombus risk)
- High_dose_norepinephrine_minimize (catecholamine excess is the underlying mechanism — escalate to MCS rather than higher pressors)

Monitoring

Regimen monitoring:
- arterial line continuous BP (ACC/AHA 2022 Class I)
- central venous access (ACC/AHA 2022)
- lactate q1-2h (CardShock, Harjola EHJ 2015)
- UOP hourly (SCAI 2019 end-organ perfusion marker)
- serial echo q24h for recovery trajectory and lvot gradient (Templin NEJM 2015 — typical recovery in days to weeks)
- telemetry continuous with qt monitoring (torsades risk from QT prolongation; check K + Mg)
- ecg at admission then q24h (T-wave inversion evolution)

Setting (outpatient) monitoring:
- Symptom check at 6 mo and 12 mo
- Repeat echo at 6 mo if any residual dysfunction at 4–8 wk recovery echo

Follow-up plan: Repeat echo at 4–8 wks to confirm complete LV recovery (Templin NEJM 2015); psych follow-up; long-term ARNI / BB after recovery debated (no RCT-grade evidence — case-by-case); recurrence ~5–10% over follow-up — patient education on stressor-mitigation
- Close-out criterion: Recovery echo + psych follow-up booked

Monitoring phase: A-line, central line, lactate clearance, urine output, telemetry (QT prolongation + torsades watch), serial echo q24h for LV recovery (typically resolves in days to weeks)

Disposition

Current setting: outpatient — 4–8 week recovery echo — confirm complete LV recovery (typical); discontinue mural-thrombus AC at 3 mo if EF normalized + apical akinesia resolved; long-term ARNI / BB debated case-by-case if residual dysfunction; psych follow-up + recurrence education

Disposition criteria:
- Complete recovery (EF ≥55 + symptom-free + AC discontinued) → routine surveillance only; no chronic engine handoff needed unless persistent dysfunction

Escalation triggers (move to higher acuity):
- Recurrent Takotsubo episode → ED + repeat full workup + reinforced stressor management
- Persistent symptoms despite normal echo → cardiac MRI for occult dysfunction

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [LIFE_THREATENING] Refractory Takotsubo CS despite cautious NE — escalate to MCS (IABP / Impella / VA-ECMO) for bridge to recovery rather than escalating pressors / inotropes (which worsen catecholamine excess)
- [LIFE_THREATENING] QT prolongation >500 ms in Takotsubo + electrolyte derangement (K <4 OR Mg <2) — torsades risk; aggressive electrolyte replacement + telemetry; MgSO4 + temporary pacing if torsades develops
- [SEVERE] Significant dynamic LVOT gradient (≥30 mmHg at rest or ≥50 mmHg with provocation) in Takotsubo CS — requires opposite physiology pathway: β-blocker (esmolol) + IV fluids + phenylephrine; AVOID inotropes / diuretics

Citations

- InterTAK consortium / Ghadri 2018 Eur Heart J expert consensus Part I + II; Templin NEJM 2015 PMID 26332547 (InterTAK registry); Lyon 2016 ESC HFA position statement on Takotsubo; ESC 2018 Takotsubo position paper [PMID:26332547](https://pubmed.ncbi.nlm.nih.gov/26332547/)
- Cited evidence (PMID 35718438) [PMID:35718438](https://pubmed.ncbi.nlm.nih.gov/35718438/)
- Cited evidence (PMID 20200382) [PMID:20200382](https://pubmed.ncbi.nlm.nih.gov/20200382/)
- Cited evidence (PMID 33704937) [PMID:33704937](https://pubmed.ncbi.nlm.nih.gov/33704937/)
- Cited evidence (PMID 37634145) [PMID:37634145](https://pubmed.ncbi.nlm.nih.gov/37634145/)

Last reconciled with current guidelines: 2026-05-15.
References
  • InterTAK consortium / Ghadri 2018 Eur Heart J expert consensus Part I + II; Templin NEJM 2015 PMID 26332547 (InterTAK registry); Lyon 2016 ESC HFA position statement on Takotsubo; ESC 2018 Takotsubo position paper — PMID:26332547
  • Cited evidence (PMID 35718438) — PMID:35718438
  • Cited evidence (PMID 20200382) — PMID:20200382
  • Cited evidence (PMID 33704937) — PMID:33704937
  • Cited evidence (PMID 37634145) — PMID:37634145